Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain-Reference-Cited by-同舟云学术

Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain

Published:2021-04-16 Issue:5 Volume:12 Page:1535-1551
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Norrbacka Kirsi^ORCID,Sicras-Mainar Antoni,Lebrec Jeremie,Artime Esther,Díaz Silvia,Tofé-Povedano Santiago,Hernández Ignacio,Romera Irene

Funder

Sponsorship for this study and article processing charges were funded by Eli Lilly and Co., Indianapolis, IN, USA

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s13300-021-01039-5.pdf

Reference46 articles.

1. International Diabetes Federation. IDF Diabetes Atlas, 9th edition. Brussels: International Diabetes Federation, 2019. http://www.idf.org/diabetesatlas. Accessed 2 June 2020.

2. Aguayo A, Urrutia I, Gonzalez-Frutos T, et al. Prevalence of diabetes mellitus and impaired glucose metabolism in the adult population of the Basque Country. Spain Diabet Med. 2017;34:662–6.

3. Soriguer F, Goday A, Bosch-Comas A, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Diabetes Study. Diabetologia. 2012;55:88–93.

4. Mata-Cases M, Casajuana M, Franch-Nadal J, et al. Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia. Spain Eur J Health Econ. 2016;17:1001–10.

5. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–701.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain;Advances in Therapy;2024-07-22

2. Epidemiology, Treatment Patterns, and Cost Analysis of Immune Thrombocytopenia in Spain between 2014 and 2020: A Population-based Study;TH Open;2024-05-31

3. Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study;Diabetes Therapy;2023-09-23

4. The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes;Diabetes, Obesity and Metabolism;2023-09-12

5. Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study;Advances in Therapy;2023-06-07